Home > Healthcare > Medical Devices > Diagnostic Devices > HLA Typing for Transplant Market
HLA Typing for Transplant Market Size
HLA Typing for Transplant Market size was worth more than USD 735 million in 2022 and is projected to expand at over 8.5% CAGR from 2023-2032.
Increasing frequency of solid organ transplant procedures will have a positive impact on the HLA typing for transplant industry dynamics. HLA typing or human leukocyte antigen typing is used to match donors and recipients during bone marrow or cord blood transplants. Rising incidences of diseases necessitating bone marrow transplants such as lymphomas, multiple myeloma, leukemia, and immune deficiency disorders, will propel the need for HLA typing.
A shortage of donors could restrain the market expansion. The presence of a substantial gap between the number of organs required and the organs donated is a major challenge for the healthcare community. Despite advances in medical technology and rigorous campaigns promoting the need for organ donors, there exists a considerable disparity between supply and demand.
| Report Attributes | Details |
|---|---|
| Base Year: | 2022 |
| Market Size in 2022: | USD 735 Million |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 8.5% |
| 2032 Value Projection: | USD 1.7 Billion |
| Historical Data for: | 2018 to 2032 |
| No. of Pages: | 255 |
| Tables, Charts & Figures: | 372 |
| Segments covered: | Technology, Product & Services, Application, End-use and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
HLA Typing for Transplant Market Analysis
HLA typing for transplant market from molecular assays technology is anticipated to exceed USD 1.5 billion by 2032. Hospitals, laboratories, and medical centers are rapidly shifting toward molecular assay technology for next-generation sequencing (NGS) in tissue typing. It offers end-users high-throughput, efficient, and DNA sequencers in HLA testing. The growing use of technologies such as NGS, PCR, and RT-PCR in healthcare will further proliferate the use of molecular assay techniques.
In terms of revenue share, the software segment of the HLA typing for transplant market is estimated to reach USD 250 million by 2032. Software assistance in HLA typing is gaining momentum as the process is time-consuming. Technological advancements have enabled the development of sophisticated software to analyze and compile data through HLA typing. Several industry players are introducing novel software to enhance the efficiency of organ transplant procedures.
HLA typing for transplant market from diagnostic labs is projected to surpass USD 943 million by 2032. Over the last few years, the number of HLA testing procedures performed at diagnostic laboratories has increased substantially on account of the increasing frequency of organ transplants. According to the Global Observatory on Donation & Transplantation, approximately 129,681 organ transplant surgeries were performed in 2020. The rising prevalence of genetic conditions, chronic disorders, and physical injuries will fuel the need for HLA typing at diagnostic labs.
North America HLA typing for transplant market was more than 35% in 2022. Developed countries like the U.S and Canada with robust healthcare infrastructure and expenditure will positively influence the regional industry landscape. Several government initiatives have been implemented to ensure the ethical execution of organ donation processes along with transplantation programs. These countries have also reported considerable growth in the demand for organ transplants in recent years.
HLA Typing for Transplant Market Share
Some of the leading companies in the HLA typing for transplant market are
- Luminex Corporation
- Pacific Biosciences of California, Inc
- Abbott Laboratories
- Bio-Rad Laboratories
- BioReference Laboratories
- CareDx, Inc.
- GenDx
- Illumina Inc.
- Fujirebio
- BAG Diagnostic GmbH
- Immucor Inc.
- Inno-train Diagnostik GmbH
- Omixon, Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- Thermo-Fisher Scientific Inc.
- GMSbiotech, Inc.
- Biofortuna Limited
- TBG Diagnostics Limited
Impact of COVID-19 Pandemic
The COVID-19 pandemic resulted in a negative impact on the HLA typing for transplant industry. Owing to the dramatically surging number of COVID-19 infections, a large number of healthcare facilities delayed or postponed non-essential surgical procedures such as organ transplants and non-invasive procedures. As a result, the need for HLA typing and sequencing systems was reduced significantly. However, the emergence of new healthcare trends and a growing preference for at-home care encouraged the development of innovative testing products enabling accurate diagnosis at home.
Global HLA typing for transplant market research report includes in-depth coverage of the industry with estimates & forecasts in terms of volume in Kilo Tons and revenue in USD Billion from 2018 to 2032 for the following segments: Click here to Buy Section of this Report
Market Size, By Technology
- Non-Molecular Assays
- Serological Assays
- Mixed Lymphocyte Culture Assays
- Molecular Assays
- PCR Based Molecular Assays
- Sequencing Based Molecular Assays
- Sanger Sequencing
- Next Generation Sequencing
Market Size, By Products & Services
- Instruments
- Reagents and Consumables
- Software
- Services
Market Size, By Application
- Diagnostics
- Research
Market Size, By Application
- Hospitals
- Diagnostic Labs
- Academic and Research Institutes
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Asia Pacific
- China
- India
- Japan
- Australia
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
Frequently Asked Questions (FAQ) :